1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Fluorouracil (5-FU) |
| brand | String | Efudex (topical), Carac (topical), Fluoroplex (topical); generic IV |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Antineoplastics|Antineoplastic]] • [[:Category:Antimetabolites|Antimetabolite (pyrimidine analog)]] |
| mechanism | String | |
| uses | String | '"`UNIQ--vote-000011BA-QINU`"', '"`UNIQ--vote-000011BB-QINU`"', '"`UNIQ--vote-000011BC-QINU`"', '"`UNIQ--vote-000011BD-QINU`"' |
| starting_dose | String | Topical: 0.5-5% cream/solution to lesions BID × 2-4 weeks; systemic IV: regimen-specific in cancer chemotherapy |
| preparations | String | 0.5% (Carac), 1% (Fluoroplex), 5% (Efudex) topical creams/solutions; 50 mg/mL IV |
| fda_max | String | Topical: nightly; systemic: regimen-specific |
| pill_id | Text | |
| routes | List of String, delimiter: , | Topical • IV |
| onset | String | Topical: inflammation, erythema, crusting at 2 weeks; complete response weeks to months after course |
| duration | String | N/A |
| halflife | String | ~10-20 minutes systemically (rapid hepatic and erythrocyte dihydropyrimidine dehydrogenase clearance)'"`UNIQ--ref-000011BE-QINU`"' |
| bioavailability | String | Topical: minimal systemic absorption (oral systemic 5-FU not used due to poor and variable absorption)'"`UNIQ--ref-000011BF-QINU`"' |
| pregnancy | String | Topical: avoid; systemic: contraindicated in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US |
